Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Meeting expected to occur approximately 30 days from the FDA's receipt of meeting request PRINCETON, N.J., April 24, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical... | June 18, 2023